11/07/2025
šµš° Pakistanās pharmaceutical industry is a rising star in the countryās economic landscape, with strong domestic performance and growing export potential. Hereās a detailed look at both sides:
---
š Industry Overview
⢠Size & Growth: Valued at over $4 billion, growing at 12% annually, with more than 750 licensed companies.
⢠ADomestic Fulfillment: Meets 95% of Pakistanās medicine demand, including generics, branded drugs, and vaccines.
⢠BKey Players: Includes multinationals like GlaxoSmithKline, Pfizer, Abbott, and strong local firms like Getz Pharma, Ferozsons, and Searle.
⢠AInnovation & R&D: While still developing, thereās increasing investment in biosimilars, biotech, and quality control labs.
⢠BRegulatory Body: The Drug Regulatory Authority of Pakistan (DRAP) oversees quality, safety, and export licensing.
š Export Landscape
⢠Export Value: Reached $421 million in 2024, with projections to grow further.
⢠⢠DTop Exported Products*: Includes antibiotics, blood thinners, steroids, multivitamins, and vaccines.
⢠Target Markets*: Africa, Central Asia, Middle East, and parts of Europe.
⢠Export Requirements*:
⢠Must be registered with DRAP.
⢠Exporters need a Drug Export License (DEL) and NOC for each consignment.
⢠Export Strategy Goals*:
⢠Improve quality standards.
⢠Promote value-added products.
⢠Build a national medicine brand.